[A22-89] Olaparib (breast cancer, adjuvant) – Benefit assessment according to §35a Social Code Book V
Last updated 16.02.2023
Commission awarded on 25.08.2022 by the Federal Joint Committee (G-BA).
Adult patients with germline BRCA-mutant, HER2-negative, high risk early breast cancer; after neoadjuvant or adjuvant chemotherapy; adjuvant treatment
Indication of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.